/NPCE
NPCE Stock - NeuroPace, Inc.
Healthcare|Medical - DevicesNASDAQ
$16.59+5.40%
+$0.85 (+5.40%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.96
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).76
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.46
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+13.0%upside
Target: $18.75
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NPCE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$16.42 – $16.76
TARGET (TP)$18.75
STOP LOSS$15.26
RISK/REWARD1:1.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.85
52W High$18.98
52W Low$7.56
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $79.91M | $65.42M | $45.52M | $45.18M | $41.14M |
| Gross Profit | $59.09M | $48.12M | $32.49M | $33.44M | $30.27M |
| Gross Margin | 73.9% | 73.6% | 71.4% | 74.0% | 73.6% |
| Operating Income | $-21,671,000 | $-27,174,000 | $-40,794,000 | $-23,737,000 | $-13,051,000 |
| Net Income | $-27,141,000 | $-32,956,000 | $-47,082,000 | $-36,080,000 | $-24,278,000 |
| Net Margin | -34.0% | -50.4% | -103.4% | -79.9% | -59.0% |
| EPS | $-0.93 | $-1.27 | $-1.91 | $-2.17 | $-2.17 |
Company Overview
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
83%
Hold / Neutral
1
17%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish1 Neutral/Bearish
Price Targets
$15
Average Target
↓ 11.8% Downside
Now
$6
Low
$15
Average
$22
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 28th 2025 | H.C. Wainwright | Initiation | Buy | $18 |
| January 21st 2025 | UBS | Initiation | Buy | $17 |
| March 14th 2024 | Wells Fargo | Upgrade | Overweight | $20← $16 |
| January 30th 2024 | Leerink Partners | Initiation | Outperform | $22 |
| November 10th 2023 | Cantor Fitzgerald | Initiation | Overweight | $11 |
| August 24th 2023 | Morgan Stanley | Upgrade | Equal Weight | $6← $5 |
| February 22nd 2023 | Lake Street | Initiation | Buy | $10 |
| April 6th 2022 | Wolfe Research | Initiation | Outperform | $13 |
Earnings History & Surprises
NPCEBeat Rate
67%
Last 18 quarters
Avg Surprise
+9.5%
EPS vs Estimate
Beats / Misses
12/5
1 met exactly
Latest EPS
$-0.11
Q4 2025
EPS Surprise History
Q1 24
+30.3%
$-0.23vs$-0.33
Q2 24
0.0%
$-0.32vs$-0.32
Q3 24
+10.3%
$-0.26vs$-0.29
Q4 24
+26.9%
$-0.19vs$-0.26
Q1 25
+28.0%
$-0.18vs$-0.25
Q2 25
+19.2%
$-0.21vs$-0.26
Q3 25
-8.3%
$-0.26vs$-0.24
Q4 25
+45.0%
$-0.11vs$-0.20
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 3, 2026 | $-0.19 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.20 | $-0.11 | +45.0% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.24 | $-0.26 | -8.3% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.26 | $-0.21 | +19.2% | ✓ BEAT |
Q1 2025 | Mar 4, 2025 | $-0.25 | $-0.18 | +28.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.26 | $-0.19 | +26.9% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.29 | $-0.26 | +10.3% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.32 | $-0.32 | 0.0% | = MET |
Q1 2024 | Mar 5, 2024 | $-0.33 | $-0.23 | +30.3% | ✓ BEAT |
Q4 2023 | Nov 6, 2023 | $-0.39 | $-0.28 | +28.2% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.47 | $-0.36 | +23.4% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.46 | $-0.41 | +10.9% | ✓ BEAT |
Q1 2023 | Mar 2, 2023 | $-0.49 | $-0.45 | +8.2% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.52 | $-0.48 | +7.7% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.44 | $-0.52 | -18.2% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.46 | $-0.47 | -2.2% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-0.33 | $-0.44 | -33.3% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.30 | $-0.34 | -13.3% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.39 | $-0.36 | +7.7% | ✓ BEAT |
Latest News
NeuroPace Submits Premarket Approval Supplement Application To FDA For Expansion Of Labeled Indication For RNS System
📈 PositiveBenzinga•Dec 17, 2025, 01:04 PM
UBS Maintains Buy on NeuroPace, Raises Price Target to $22
📈 PositiveBenzinga•Dec 16, 2025, 02:27 PM•Also:
JP Morgan Maintains Overweight on NeuroPace, Raises Price Target to $20
📈 PositiveBenzinga•Dec 10, 2025, 03:59 PM
NeuroPace Presents Preliminary 18-Month Safety And Effectiveness Results From Ongoing NAUTILUS1 Trial Evaluating RNS System As Adjunctive Therapy For Treatment Of ASM Resistant IGE With GTC Seizures, At AES Meeting
📈 PositiveBenzinga•Dec 8, 2025, 01:10 PM
JP Morgan Maintains Overweight on NeuroPace, Raises Price Target to $18
📈 PositiveBenzinga•Nov 5, 2025, 07:36 PM
Wells Fargo Maintains Overweight on NeuroPace, Raises Price Target to $16
📈 PositiveBenzinga•Nov 5, 2025, 03:16 PM
Neuropace shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositiveBenzinga•Nov 5, 2025, 02:13 PM
Neuropace shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositiveBenzinga•Nov 4, 2025, 09:49 PM
NeuroPace Raises FY2025 Sales Guidance from $94.000M-$98.000M to $97.000M-$98.000M vs $95.674M Est
📈 PositiveBenzinga•Nov 4, 2025, 09:09 PM
NeuroPace Q3 EPS $(0.11) Beats $(0.19) Estimate, Sales $27.354M Beat $24.634M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 09:08 PM
NeuroPace Revenue Jumps 22 Percent in Q2
📈 PositiveThe Motley Fool•Aug 13, 2025, 02:06 AM
NeuroPace Reports Record Q2 Revenue
📈 PositiveThe Motley Fool•Aug 12, 2025, 09:48 PM
NeuroPace falls after setback in trial for neuromodulation system
📉 NegativeSeeking Alpha•May 27, 2025, 01:04 PM
Frequently Asked Questions about NPCE
What is NPCE's current stock price?
NeuroPace, Inc. (NPCE) is currently trading at $16.59 per share. The stock has moved +5.40% today.
What is the analyst price target for NPCE?
The average analyst price target for NPCE is $18.75, based on 1 analyst.
What sector is NeuroPace, Inc. in?
NeuroPace, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is NPCE's market cap?
NeuroPace, Inc. has a market capitalization of $0.55 billion, making it a small-cap company.
Does NPCE pay dividends?
No, NeuroPace, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALDX
Aldeyra Therapeutics, Inc.
$4.96
Mkt Cap: $0.3B
BWAY
BrainsWay Ltd.
$17.11
Mkt Cap: $0.3B
CERS
Cerus Corporation
$2.09
Mkt Cap: $0.4B
CVRX
CVRx, Inc.
$8.03
Mkt Cap: $0.2B
DCTH
Delcath Systems, Inc.
$10.06
Mkt Cap: $0.3B
GNLX
Genelux Corporation
$4.20
Mkt Cap: $0.2B
MASS
908 Devices Inc.
$5.84
Mkt Cap: $0.2B
RXST
RxSight, Inc.
$12.03
Mkt Cap: $0.5B
SENS
Senseonics Holdings, Inc.
$6.15
Mkt Cap: $0.3B
SGHT
Sight Sciences, Inc.
$8.45
Mkt Cap: $0.4B
Explore stocks similar to NPCE for comparison